Do prostaglandin analogs affect eyelid position and motility?

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 5, 2011, Pages 511-517

  Altieri, Michele ^a   Ferrari, Ettore ^a  

^a Hospital of Imperia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ACCURACY; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECTROPION; ENTROPION; EYE MOVEMENT; EYE POSITION; EYELID; EYELID MUSCLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PTOSIS; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AMIDES; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; CLOPROSTENOL; CROSS-SECTIONAL STUDIES; EYELIDS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; SINGLE-BLIND METHOD;

EID: 80054865432     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0003     Document Type: Article

References (47)

1. Alexander, C.L., Miller, S.J., and Abel, S.R. Prostaglandin analogues treatment of glaucoma and ocular hypertension. Ann. Pharmacother. 36:504-511, 2002. (Pubitemid 34205326)
2. Linden, C. Therapeutic potential of prostaglandin analogues in glaucoma. Expert Opin. Investig. Drugs 10:679-694, 2001. (Pubitemid 32288186)
3. Gabelt, B.T., and Kaufman, P.L. Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. ExEye Res. 49:389-402, 1989. (Pubitemid 19239397)
4. Nilsson, S.F., Samuelsson, M., Bill, A., and Stjernschantz, J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1- isopropylester in the cynomolgus monkey. ExEye Res. 48:707-716, 1989. (Pubitemid 19143452)
5. Thierauch, K.H., Dinter, H., and Stock, G. Prostaglandins and their receptors. I. Pharmacologic receptor description, metabolism and drug use. J. Hypertension 11:1315-1318, 1993.
6. Richter, M., Krauss, A.H., Woodward, D.F., and Lutjen- Drecoll, E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonist and a prostamide. Invest. Ophthalmol. Vis. Sci. 44:4419-4426, 2003. (Pubitemid 37186278)
7. Lutjen-Drecoll, E., and Tamm, E. Morphological study of the anterior segment of cynomologus monkey eyes following treatment with prostaglandin F2α. ExEye Res. 47:761-769, 1988.
8. Berg, A., Hultgard-Ekwall, A.K., Rubin, K., Stjernaschantz, J., and Reed, R. Effect of PGE1, PGI2, and PGF2α analogues on collagen gel compaction in vitro and interstitial pressure in vivo. Am. J. Physiol. Heart Circ. Physiol. 43:663-671, 1998.
9. Weinreb, R.N. Enhancement of scleral macromolecular permeability with prostaglandins. Trans. Am. Ophthalmol.Soc. 99:319-343, 2001. (Pubitemid 40525416)
10. Weinreb, R.N., Lindsey, J.D., Marchenko, N., Angert, M., and Strongin, A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest. Ophthalmol. Vis. Sci. 45:4368-4377, 2004. (Pubitemid 39564662)
11. Brubaker, R.F. Mechanism of action of bimatoprost (Lumigan TM). Surv. Ophthalmol.45(Suppl 4):S347-S351, 2001.
12. Eisenberg, D.L., Toris, C., and Camras, C.B. Bimatoprost and travoprost. A review of recent studies of two new glaucoma drugs. Surv. Ophthalmol.47(Suppl 1):S101-S115, 2002.
13. Brubaker, R.F., Schoeff, E.O., and Nau, C.B. Effects of bimatoprost, a new ocular hypotensive agent, on aqueous humor dynamics. Am. J. Ophthalmol.131:19-24, 2001. (Pubitemid 32037003)
14. Camras, C.B. Safety and side effects of latanoprost. In: Weinreb, R.N., Kitazawa, Y., and Krieglestein, G.K., eds. Glaucoma in the 21st Century. London: Harcourt Health Communications; 2000; p201-203.
15. Stewart, W.C., Kolker, A.E., Stewart, J.A., Leech, J., and Jackson, A.L. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost and travoprost. Am. J. Ophthalmol.135:314-320, 2003. (Pubitemid 36279517)
16. Camras, C.B., Toris, C.B., and Tamesis, R.R. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging 15:377-388, 1999. (Pubitemid 29527872)
17. DuBiner, H., Cooke, D., Dirks, M., et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv. Ophthalmol.45(Suppl 4):S353-S360, 2001.
18. Mukhopadhyay, R., and Plumb, A. A rare complication from prostaglandin analogue therapy. Clin. ExOptom. 92:137-138, 2009.
19. Casson, R.J., and Selva, D. Lash ptosis caused by latanoprost. Am. J. Opthalmol. (5):932-933, 2005. (Pubitemid 40614793)
20. Centofanti, M., Oddone, F., Chimenti, S., et al. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am. J. Ophthalmol.142:1059-1060, 2006. (Pubitemid 44853893)
21. Mietz, H., Esser, J.M., Welsandt, G., et al. Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 44:5182-5188, 2003. (Pubitemid 37475387)
22. Collins, J.R.O. Entropion and trichiasis. In: Collins, J.R.O., ed. Manual of Systematic Eyelid Surgery. London: Churchill Livingstone; 1989; p7-9.
23. Collins, J.R.O. Ectropion. In: Collins, J.R.O., ed. Manual of Systematic Eyelid Surgery. London: Churchill Livingstone; 1989; p27-28.
24. Collins, J.R.O. Ptosis. In: Collins, J.R.O., ed. Manual of Systematic Eyelid Surgery. London: Churchill Livingstone; 1989; p49-50, 54.
25. European Glaucoma Society. Classification and terminology. In: Terminology and Guidelines for Glaucoma. Savona, Italy: Dogma; 2003; Chapter 2; p5-8.
26. Frueh, B.R., and Musch, D.C. Evaluation of levator muscle integrity in ptosis with levator force measurement. Ophthalmology 103:244-250, 1996. (Pubitemid 26066205)
27. Shore, J. Changes in lower eyelid resting position, movement and tone with age. Am. J. Ophthalmol.99:414-423, 1985.
28. Wright, M., Bell, D., Scott, C., and Leatherbarrow, B. Everting sutures correction of lower lid involutional entropion. Br. J. Ophthalmol.83:1060-1063, 1999. (Pubitemid 29433430)
29. Altieri, M., Iester, M., Harman, F., et al. Comparison of three techniques for repair of involutional lower lid entropion: A three-year follow-up study. Ophthalmol.ogica 217: 265-272, 2003. (Pubitemid 36693889)
30. Altieri, M., Kingston, A.E.H., Bertagno, R., and Altieri, G. A modified technique of retractors plication in entropion repair: A four year follow-up study. Can. J. Ophthalmol.39:650-655, 2004. (Pubitemid 39472085)
31. Vallabhanath, P., and Carter, S.R. Ectropion and entropion. Curr. Opin. Ophthalmol.11:345-351, 2002.
32. Altieri, M., Truscott, E., Kingston, A.E.H., et al. Ptosis secondary to anterior segment surgery and its repair in a two year follow-up study. Ophthalmol.ogica 219:129-135, 2005. (Pubitemid 40868780)
33. Arcieri, E.S., Santana, A., Rocha, F.N., Guapo, G.L., and Costa, V.P. Blood aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia. Arch. Ophthalmol.123:186-192, 2005. (Pubitemid 40189705)
34. Hylton, C., and Robin, A.L. Update on prostaglandin analogues. Curr. Opin. Ophthalmol.14:65-69, 2003.
35. Parentin, F. Granulomatous anterior uveitis associated with bimatoprost: A case report. Ocul. Immunol. Inflamm. 11:67-71, 2003. (Pubitemid 36918647)
36. Stewart, W.C., Stewart, J.A., Jenkins, J.N., and Jackson, A.L. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. J. Glaucoma. 12:475-479, 2003. (Pubitemid 37494175)
37. Faulkner, W.J., and Burk, S.E. Acute anterior uveitis and corneal edema associated with travoprost. Arch. Ophthalmol.121:1054-1055, 2003. (Pubitemid 36841806)
38. Johnstone, M.A. Hypertricose and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am. J. Ophthalmol.124:544-547, 1997. (Pubitemid 27425878)
39. Strober, B.E., Potash, S., and Grossma, M.E. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis 67:109-110, 2001. (Pubitemid 33756241)
40. Sugimoto, M., Sugimoto, M., and Uji, Y. Quantitative analysis of eyelashes lenghting following topical latanoprost therapy. Can. J. Ophthalmol.37:342-345, 2002. (Pubitemid 35351018)
41. Costagliola, C., Del Prete, A., Verolino, M., et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by betablockers twice daily: A 3-year follow-uExperience and incidence of side effects in a prospective study on 76 patients. Graefes Arch. Clin. ExOphthalmol.240:379-386, 2002. (Pubitemid 36075612)
42. Kahook, M.Y., and Ammar, D.A. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. Adv. Ther. 26:970-975, 2009.
43. Honda, N., Miyai, T., Neijma, B., et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch. Ophthalmol.128:466-471, 2010.
44. Law, S.K. Bimatoprost in the treatment of eyelash hypotrichosis. Clin. Ophthalmol.26:349-358, 2010.
45. Faghihi, G., Andalib, F., and Asilian, A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur. J. Dermatol. 19:586-587, 2009.
46. Wester, S.T., Lee, W.W., and Shi, W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology 117:1024-1031, 2010.
47. Schlote, T. Side-effects and risk profile of latanoprost 0.005%. Ophthalmol.oge 99:724-729, 2002. (Pubitemid 36358260)